---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023218"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:15:15.101656+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences Q3 net loss $23.1M; CEO retirement, new pipeline programs announced

## Summary
- Net loss of $23.1M ($0.48 per share) vs $18.8M ($0.41) in Q3 2021.
- Cash and marketable securities $108.7M; projected to fund operations into H1 2024.
- R&D expenses $18.1M, down slightly from $18.5M YoY.
- CEO John McHutchison to retire end of 2022; President Jason Okazaki named successor.
- Phase 1a trial of next-gen core inhibitor ABI-4334 initiated; new HSV-2 and herpesvirus programs introduced.

## SEC filing metadata
- accession: 0000950170-22-023218
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017022023218/0000950170-22-023218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017022023218/asmb-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023218
- JSON: https://secwatch.observer/filing/0000950170-22-023218.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023218.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income Net loss attributable to common stockholders was $23.1 million, or $0.48 per basic and diluted share, EPS $0.48 per basic and diluted share.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss attributable to common stockholders was $23.1 million, or $0.48 per basic and diluted share
  - EPS: $0.48 per basic and diluted share
  - Result: reported results
  source text: Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000095017022023218/0000950170-22-023218-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.